Clinical Trial Update: AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

View source ↗

Summary

A clinical trial sponsored by Roswell Park Cancer Institute is recruiting to evaluate an AI-derived biomarker to guide neoadjuvant treatment for borderline rese…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Pancreatic Ductal Adenocarcinoma | Status: RECRUITING